Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Iovance Biotherapeutics second quarter 2026 conference call. My name is Daniel, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Please note that this conference call is being recorded. I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara, you may begin. Thank you, operator. Good morning, and welcome to the Iovance webcast to discuss our second quarter of 2026 financial results, business achievements, and corporate updates. This morning, we issued a press release that is available on our corporate website at iovance.com. This conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue and revenue guidance, commercial activities, Clinical Trials and Results, Regulatory Approvals, Submissions, Feedback and Guidance, Plans and Strategies, Research and Preclinical Activities, Potential Future Applications of Our Technologies, Manufacturing Capabilities, Payer Interactions, Licenses and Collaborations, Cash Position and Future Updates. Forward-looking statements are subject to numerous risks and uncertainties. Many of which are beyond our control, including the risks and uncertainties described from time to time in our FTC filing. Our results may differ materially from those projected during today's call. We undertake no obligation to publicly update any forward-looking statements. I will turn the call over now to Dr. Fred Vogt, Interim CEO and President. Thank you, Sara. IVANCE is the global leader in innovating, developing, and delivering tilt therapy for solid tumors. Today and for the...